Kongenitale hämolytische Anämien durch Membran- und Enzymdefekte der Erythrozyten

Membran- und Enzymdefekte der Erythrozyten können schwere, zum Teil chronisch transfusionsbedürftige Anämien verursachen und mit akut anämisierenden aplastischen Krisen einhergehen. Die exakte Kenntnis dieser Anämien ermöglicht eine patientenorientierte personale Therapie.

Abstract

Erythrocyte membrane and enzyme defects are the most common cause of congenital hemolytic anemias in the Central European population. Diagnostics include erythrocyte morphology, special biochemical tests such as osmotic fragility (AGLT) and EMA. For enzymopenic hemolytic anemias, cost-effective biochemical analysis remains the gold standard, supplemented by molecular genetic diagnostics when appropriate. Therapeutically, near complete splenectomy reduces hemolysis significantly for spherocytosis. The residual spleen at least provides a considerable phagocytic function and better response to immunisation and by inference possibly better protection against severe post-splenectomy infection. For pyruvate kinase deficiency, which is not so rare, a new molecular therapy (Mitapivat) is currently being introduced. In G6PD deficiency, there are very few drugs that cause hemolytic crisis. Sudden onset of hemoglobinuria is an early important hallmark of severe hemolytic crisis in G6PD deficiency and these patients should be hospitalized. Aplastic crises in the setting of parvovirus B19 infection occur in all congenital hemolytic anemias. Transfusion is not preventable in most cases. Iron-excreting treatment is required in the rare patients in need of chronic transfusion.

Schlüsselwörter

Hereditäre Sphärozytose - Hereditäre Elliptozytose - Hereditäre Stomatozytose - Pyruvatkinase-Mangel Pyrimidin-5’-Nucleotidase Mangel - Glucose-6-Phosphat-Dehydrogenase-Mangel

Key words

hereditary spherocytosis - hereditary ellipocytosis - hereditary stomatocytosis - pyruvate kinase deficiency - pyrimidin 5’-nucleotidase deficiency - G6PD deficiency

Publication History

Article published online:
20 September 2022

• Literatur

• 1 An X, Mohandas N. Disorders of red cell membrane. Br J Haematol 2008; 141: 367-375 DOI: 10.1111/j.1365-2141.2008.07091.x.
• 2 Vagace JM, Bajo R, Gervasini G. Diagnostic and therapeutic challenges of primary autoimmune haemolytic anaemia in children. Arch Dis Child 2014; 99: 668-673 DOI: 10.1136/archdischild-2013-305748.
• 3 Gallagher PG. Disorders of red cell volume regulation. Curr Opin Hematol 2013; 20: 201-207 DOI: 10.1097/MOH.0b013e32835f6870.
• 4 Zamora EA, Schaefer CA. Hereditary Spherocytosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022
• 5 Da Costa L, Galimand J, Fenneteau O. et al. Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev 2013; 27: 167-178 DOI: 10.1016/j.blre.2013.04.003.
• 6 Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet 2008; 372: 1411-1426 DOI: 10.1016/s0140-6736(08)61588-3.
• 7 Eber S, Andres O. Hereditäre Sphärozytose. AWMF S1 Leitlinie, Register Nr. 025/018. 2016
• 8 He Y, Jia S, Dewan RK. et al. Novel mutations in patients with hereditary red blood cell membrane disorders using next-generation sequencing. Gene 2017; 627: 556-562 DOI: 10.1016/j.gene.2017.07.009.
• 9 Iolascon A, Avvisati RA, Piscopo C. Hereditary spherocytosis. Transfus Clin Biol 2010; 17: 138-142 DOI: 10.1016/j.tracli.2010.05.006.
• 10 He BJ, Liao L, Deng ZF. et al. Molecular Genetic Mechanisms of Hereditary Spherocytosis: Current Perspectives. Acta Haematol 2018; 139: 60-66 DOI: 10.1159/000486229.
• 11 Bolton-Maggs PH, Langer JC, Iolascon A. et al. Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. Br J Haematol 2012; 156: 37-49 DOI: 10.1111/j.1365-2141.2011.08921.x.
• 12 Kiliç MA, Özdemir GN, Tahtakesen TN. et al. Clinical Features and Outcome of Children With Hereditary Spherocytosis. J Pediatric Hematol Oncol 2022; 44: e306-e309 DOI: 10.1097/MPH.0000000000002211.
• 13 Kobayashi Y, Hatta Y, Ishiwatari Y. et al. Human parvovirus B19-induced aplastic crisis in an adult patient with hereditary spherocytosis: a case report and review of the literature. BMC Res Notes 2014; 7: 137 DOI: 10.1186/1756-0500-7-137.
• 14 Steward SC, Chauvenet AR, OʼSuoji CC. Hereditary spherocytosis: Consequences of delayed diagnosis. SAGE Open Medicine 2014; 2 DOI: 10.1177/2050312114547093.
• 15 Eber S, Lux SE. Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer. Semin Hematol 2004; 41: 118-141
• 16 Bobée V, Daliphard S, Schrapp A. et al. Screening of hereditary spherocytosis and pyruvate kinase deficiency by automated blood count using erythrocytic and reticulocytic parameters. Int J Lab Hematol 2018; 40: 697-703 DOI: 10.1111/ijlh.12906.
• 17 Nair SC, Arora NK, Jain S. et al. Mean reticulocyte volume enhances the utility of red cell mean sphered cell volume in differentiating peripheral blood spherocytes of hereditary spherocytosis from other causes. Ind J Pathol Microbiol 2015; 58: 307-309
• 18 Casale M, Perrotta S. Splenectomy for hereditary spherocytosis: complete, partial or not at all?. Expert Rev Hematol 2011; 4: 627-635 DOI: 10.1586/ehm.11.51.
• 19 Pincez T, Guitton C, Gauthier F. et al. Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study. Blood 2016; 127: 1616-1618 DOI: 10.1182/blood-2015-11-679357.
• 20 Pincez T, Guitton C, Landman-Parker J. et al. Subtotal and total splenectomy for hereditary pyropoikilocytosis: Benefits and outcomes. Am J Hematol 2018; 93: E340-E342 DOI: 10.1002/ajh.25223.
• 21 Stoehr GA, Sobh JN, Luecken J. et al. Near-total splenectomy for hereditary spherocytosis: clinical prospects in relation to disease severity. Brit J Haematol 2006; 132: 791-793
• 22 Stoehr GA, Luecken J, Zielen S. et al. Mode of splenectomy and immunogenicity of meningococcal vaccination in patients with hereditary spherocytosis. Brit J Surg 2008; 95: 466-471 DOI: 10.1002/bjs.6008.
• 23 Matsumoto R, Yoshiyama K, Yokoyama S. et al. Surgical resection of extramedullary haematopoiesis in the posterior mediastinum. Respirol Case Rep 2018; 6: e00358 DOI: 10.1002/rcr2.358.
• 24 Mühlberger D. Deutsche Gesellschaft für Phlebologie. Diagnostik und Therapie des Ulcus cruris venosum; Überarbeitung AWMF Leitlinie S2k, Register Nr. 037-009; geplante Fertigstellung 12/2022.
• 25 Wang GJ, Gao CF, Wei D. et al. Acute pancreatitis: etiology and common pathogenesis. World J Gastroenterol 2009; 15: 1427-1430 DOI: 10.3748/wjg.15.1427.
• 26 Andolfo I, Russo R, Gambale A. et al. Hereditary stomatocytosis: An underdiagnosed condition. Am J Hematol 2018; 93: 107-121 DOI: 10.1002/ajh.24929.
• 27 Gesellschaft für Pädiatrische Onkologie und Hämatologie. Diagnostik und Therapie der sekundären Eisenüberladung bei Patienten mit angeborenen Anämien, AWMF Leitlinie S2k. Registernummer 025-029. 2022
• 28 Butorac Ahel I, Baraba Dekanic K, Palcevski G. et al. An Infant With Unusually High Unconjugated Hyperbilirubinemia Due to Coexistence of Hereditary Spherocytosis and Gilbert Syndrome. J Ped Hematol Oncol 2018; 40: e127-e128 DOI: 10.1097/mph.0000000000001025.
• 29 Vayá A, Suescun M, Pardo A. et al. Erythrocyte deformability and hereditary elliptocytosis. Clin Hemorheol Microcirc 2014; 58: 471-473 DOI: 10.3233/ch-141889.
• 30 Niss O, Chonat S, Dagaonkar N. et al. Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood Cells Mol Dis 2016; 61: 4-9 DOI: 10.1016/j.bcmd.2016.07.003.
• 31 Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol 2004; 41: 142-164 DOI: 10.1053/j.seminhematol.2004.01.003.
• 32 Singh V, Roberts S, Baden H. Hereditary stomatocytosis. Eur J Haematol 2008; 81: 410 DOI: 10.1111/j.1600-0609.2008.01118.x.
• 33 Eber S. Angeborene Erythrozytenmembrandefekte. In: Gadner H, Gaedicke G, Niemeyer C. et al., Hrsg. Pädiatrische Hämatologie und Onkologie. Berlin, Heidelberg: Springer; 2006: 123-138 DOI: 10.1007/3-540-29036-2_9
• 34 Frederiksen H. Dehydrated hereditary stomatocytosis: clinical perspectives. J Blood Med 2019; 10: 183-191 DOI: 10.2147/jbm.S179764.
• 35 Layton DM, Bain BJ. Dehydrated hereditary stomatocytosis. Am J Hematol 2016; 91: 266 DOI: 10.1002/ajh.24212.
• 36 Halma J, Petrikin J, Daniel JF. et al. Dehydrated Hereditary Stomatocytosis Presenting as Severe Perinatal Ascites and Cholestasis. J Pediatr Gastroenterol Nutr 2019; 68: e52-e53 DOI: 10.1097/mpg.0000000000002077.
• 37 Zama D, Giulietti G, Muratore E. et al. A novel PIEZO1 mutation in a patient with dehydrated hereditary stomatocytosis: a case report and a brief review of literature. Ital J Pediatr 2020; 46: 102 DOI: 10.1186/s13052-020-00864-x.
• 38 Jenner B, Brockelsby J, Thomas W. Dehydrated hereditary stomatocytosis causing fetal hydrops and perinatal ascites. Brit J Haematol 2018; 182: 620-620 DOI: 10.1111/bjh.15272.
• 39 Alberto Z, Paola B, Elisa F. Pyruvate kinase deficiency. Haematologica 2007; 92: 721-723 DOI: 10.3324/haematol.11469.
• 40 Handin RI, Lux SE, Stossel TP. Blood: Principles and Practice of Hematology. Philadelphia: Lippincott Williams and Wilkins; 1995
• 41 Pekrun A, Lakomek M, Eber S. et al. Diagnosis of pyruvate kinase deficiency in the presence of an elevated reticulocyte count. Dtsch Med Wochenschr 1995; 120: 1620-1624 DOI: 10.1055/s-2008-1055521.
• 42 Al-Samkari H, Galactéros F, Glenthøj A. et al. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. N Engl J Med 2022; 386: 1432-1442 DOI: 10.1056/NEJMoa2116634.
• 43 Rees DC, Duley JA, Marinaki AM. Pyrimidine 5′ Nucleotidase Deficiency. Br J Haematol 2003; 120: 375-383 DOI: 10.1046/j.1365-2141.2003.03980.x.
• 44 Youngster I, Arcavi L, Schechmaster R. et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010; 33: 713-726 DOI: 10.2165/11536520-000000000-00000.
• 45 Eber S, Andres O. Anämien. Monatsschr Kinderheilk 2016; 164: 59-72 DOI: 10.1007/s00112-015-0020-8.
• 46 van Wijk R, van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood 2005; 106: 4034-4042 DOI: 10.1182/blood-2005-04-1622.